U.S. Supreme Court justices divided over Teva patent battle

A general view of the U.S. Supreme Court building at sunrise is seen in WashingtonBy Lawrence Hurley WASHINGTON (Reuters) – The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd’s high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Teva is battling to protect a key patent for the drug that is due to expire in September 2015. The $4-billion-a-year drug accounts for 50 percent of Teva profits, and the patent fight is one of the most important business cases of the current term for the nine Supreme Court justices. …

Share this article